# US 11,999,719 B2 · Solid form of compound

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 11,999,719 B2
- Document ID: US11999719B2
- Status: Granted
- Kind: B2
- Application number: 18/347,335
- Filed: 2023-07-05
- Published: 2024-02-15
- Granted: 2024-06-04
- Earliest claimed: 2020-08-03
- Assignees: Inxmed (Nanjing) Co., Ltd.
- Applicants: Inxmed (Nanjing) Co., Ltd.
- Inventors: Zaiqi Wang; Jing Gao; Yingxia Sang
- Web page: https://patentgrep.com/patent/US11999719B2

## CPC

- A61P 35/00: Antineoplastic agents
- C07D 401/14: containing three or more hetero rings
- C07C 57/145: Maleic acid
- C07C 59/255: Tartaric acid
- C07C 63/08: Salts thereof
- C07B 2200/13: Crystalline forms, e.g. polymorphs
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07B: GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR (preparation of carboxylic acid esters by telomerisation C07C67/47; telomerisation C08F)

## Abstract

Provided is a solid form of a compound of formula (I) or a salt thereof, or a solvate thereof, or a solvate of a salt thereof, or a mixture thereof.

## Claims

### Claim 1

A crystalline form A of a compound of formula (I):
which is a free base of the compound of formula (I), characterized by an X-ray powder diffraction (XRPD) pattern comprising peaks at 10.979, 19.26, 21.581 and 24.801 degrees 2θ.

### Claim 2

A crystalline form I of a salt of a compound of formula (I):
which is a tartrate salt of the compound of formula (I), characterized by an X-ray powder diffraction (XRPD) pattern comprising peaks at 10.34, 17.981, 18.281 and 21.901 degrees 2θ.

### Claim 3 (depends on 1)

A pharmaceutical composition, comprising the crystalline form A of claim 1.

### Claim 4 (depends on 2)

A pharmaceutical composition, comprising the crystalline form I of claim 2.

### Claim 5 (depends on 1)

The crystalline form A of claim 1, wherein the X-ray powder diffraction (XRPD) pattern further comprises peaks at 4.781 and 22.26 degrees 2θ.

### Claim 6 (depends on 5)

The crystalline form A of claim 5, wherein the X-ray powder diffraction (XRPD) pattern further comprises peaks at 9.58, 11.459, 14.678, 17.402, 22.54, and 29.219 degrees 2θ.

### Claim 7 (depends on 6)

The crystalline form A of claim 6, wherein the X-ray powder diffraction (XRPD) pattern further comprises peaks at 7.361, 7.619, 10.54, 12.34, 12.96, 13.278, 18.54, 19.918, 23.521, 24.217, and 25.181 degrees 2θ.

### Claim 8 (depends on 1)

The crystalline form A of claim 1, wherein the X-ray powder diffraction (XRPD) pattern further comprises peaks at 4.781, 5.255, 6.395, 7.361, 7.619, and 9.58 degrees 2θ.

### Claim 9 (depends on 2)

The crystalline form I of claim 2, wherein the X-ray powder diffraction (XRPD) pattern further comprises peaks at 4.627 and 23.121 degrees 2θ.

### Claim 10 (depends on 9)

The crystalline form I of claim 9, wherein the X-ray powder diffraction (XRPD) pattern further comprises peaks at 13.019, 21.2, 27.299, 27.541 and 29.879 degrees 2θ.

### Claim 11 (depends on 10)

The crystalline form I of claim 10, wherein the X-ray powder diffraction (XRPD) pattern further comprises peaks at 15.76, 16.54, 17.159, 20.538, 24.721, 25.659, 32.277, and 41.821 degrees 2θ.

### Claim 12 (depends on 2)

The solid crystalline form I of claim 2, wherein the X-ray powder diffraction (XRPD) pattern further comprises peaks at 4.637 and 9.143 degrees 2θ.